Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Thyroid Research
Published in: Thyroid Research 1/2013

Open Access 01-12-2013 | Review

Management of hyperparathyroidism (PHP) in MEN2 syndromes in Europe

Author: Maria Alevizaki

Published in: Thyroid Research | Special Issue 1/2013

Login to get access

Abstract

Hyperparathyroidism occurs in 20-30% of MEN2A syndrome patients. It is usually associated with mild disease and is frequently asymptomatic, especially in younger age. There is genotype/phenotype association and PHP is usually associated with codon 634 mutations; however association with more “rare” mutations has also been reported. The pathology of the parathyroid glands includes hyperplasia, adenoma or a combination of the two. The optimal surgical management of this entity has not been defined yet.
Literature
1.
Schuffenecker I, Virally-Monod M, Brohet R, Goldgar D, Conte-Devolx B, Leclerc L, Chabre O, Boneu A, Caron J, Houdent C, Modigliani E, Rohmer V, Schlumberger M, Eng C, Guillausseau PJ, Lenoir GM: Risk and penetrance of primary hyperparathyroidism in multiple endocrine neoplasia type 2A families with mutations at codon 634 of the RET proto-oncogene. Groupe D'etude des Tumeurs à Calcitonine. J Clin Endocrinol Metab 1998, 83: 487–491. 10.1210/jc.83.2.487PubMed
2.
Karga HJ, Karayianni MK, Linos DA, Tseleni SC, Karaiskos KD, Papapetrou PD: Germ line mutation analysis in families with multiple endocrine neoplasia type 2A or familial medullary thyroid carcinoma. Eur J Endocrinol 1998, 139: 410–415. 10.1530/eje.0.1390410CrossRefPubMed
3.
Kraimps JL, Denizot A, Carnaille B, Henry JF, Proye C, Bacourt F, Sarfati E, Dupond JL, Maes B, Travagli JP, Boneu A, Roger P, Houdent C, Barbier J, Modigliani E: Primary hyperparathyroidism in multiple endocrine neoplasia type IIa: retrospective French multicentric study. Groupe d'Etude des Tumeurs á Calcitonine (GETC, French Calcitonin Tumors Study Group), French Association of Endocrine Surgeons. World J Surg 1996, 20: 808–812. 10.1007/s002689900123CrossRefPubMed
4.
Raue F, Frank-Raue K: Genotype-phenotype relationship in multiple endocrine neoplasia type 2. Implications for clinical management. Hormones (Athens) 2009, 8: 23–28. 10.14310/horm.2002.1218CrossRef
5.
Herfarth KK, Bartsch D, Doherty GM, Wells SA Jr, Lairmore TC: Surgical management of hyperparathyroidism in patients with multiple endocrine neoplasia type 2A. Surgery 1996, 120: 966–973. 10.1016/S0039-6060(96)80042-0CrossRefPubMed
6.
Marcocci C, Chanson P, Shoback D, Bilezikian J, Fernandez-Cruz L, Orgiazzi J, Henzen C, Cheng S, Sterling LR, Lu J, Peacock M: Cinacalcet reduces serum calcium concentrations in patients with intractable primary hyperparathyroidism. J Clin Endocrinol Metab 2009, 94: 2766–2772. 10.1210/jc.2008-2640PubMedCentralCrossRefPubMed
7.
Yoshida S, Imai T, Kikumori T, Wada M, Sawaki M, Takada H, Yamada T, Sato S, Sassa M, Uchida H, Watanabe R, Kagawa C, Nakao A, Kiuchi T: Long term parathyroid function following total parathyroidectomy with autotransplantation in adult patients with MEN2A. Endocr J 2009, 56: 545–551. 10.1507/endocrj.K09E-005CrossRefPubMed
8.
Raue F, Kraimps JL, Dralle H, Cougard P, Proye C, Frilling A, Limbert E, Llenas LF, Niederle B: Primary hyperparathyroidism in multiple endocrine neoplasia type 2A. J Intern Med 1995, 238: 369–373. 10.1111/j.1365-2796.1995.tb01212.xCrossRefPubMed
9.
Scholten A, Schreinemakers JM, Pieterman CR, Valk GD, Vriens MR, Borel Rinkes IH: Evolution of surgical treatment of primary hyperparathyroidism in patients with multiple endocrine neoplasia type 2A. Endocr Pract 2011, 17: 7–15.CrossRefPubMed
10.
Carling T, Udelsman R: Parathyroid surgery in familial hyperparathyroid disorders. J Intern Med 2005, 257: 27–37. 10.1111/j.1365-2796.2004.01428.xCrossRefPubMed
Metadata
Title
Management of hyperparathyroidism (PHP) in MEN2 syndromes in Europe
Author
Maria Alevizaki
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Thyroid Research / Issue Special Issue 1/2013
Electronic ISSN: 1756-6614
DOI
https://doi.org/10.1186/1756-6614-6-S1-S10

Other articles of this Special Issue 1/2013

Thyroid Research 1/2013 Go to the issue

Review

Clinical comments related to medullary thyroid cancer diagnosis and management

Review

Timing and criteria for prophylactic thyroidectomy in asymptomatic RET carriers – the role of Ct serum level

Review

Serum calcitonin estimation in medullary thyroid cancer: basal or stimulated levels?

Review

Results and summary of voting among the audience during presentation and discussion of Medullary Thyroid Carcinoma clinical guidelines prepared by American Thyroid Association

Review

The optimal range of RET mutations to be tested: European comments to the guidelines of the American Thyroid Association

Review

Postoperative follow up in patients showing no evident residual disease - cut-offs for imaging/ intervention
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits